Clinical Prognosis and Progression of Myasthenia Gravis Patients
Clinical Prognosis and Progression of Myasthenia Gravis Patients
This study collects the clinical data of myasthenia gravis (MG) patients, assesses outcomes
 and adverse effects of different treatment regimens, and searches for risk factors of
 conversion to generalized MG.
This is a multicenter, observational cohort trial in the real-world clinical setting
 recruiting MG patients from Neurology Departments of 6 hospitals in different regions of
 China. Clinical manifestations, laboratory test results, chest imaging and history of
 thymectomy are recorded. Patients will be classified by clinical manifestation as well as
 antibody status, and treatment regimens are determined according to the physician's judgment
 and preferences of the patients. Patients are followed up prospectively on regular to assess
 the outcomes of treatments and monitor any side effects. Peripheral blood samples are
 collected annually. Patients' clinical records are uploaded to an online database. The
 investigators plan to recruit a final sample of 2000 patients for analysis.
Inclusion Criteria:

 1. Age >14.

 2. Clinical Diagnosis of MG with supporting evidence:

 1. unequivocal clinical response to pyridostigmine

 2. positive antibody testing

 3. decrement >10% in repetitive nerve stimulations study (RNS) .

 3. Willingness to sample collection, imaging study and other disease-related examinations
 and assessments.

 4. Patients with informed consent.

 Exclusion Criteria:

 1. History of chronic degenerative, psychiatric, or neurologic disorder other than MG
 that can produce weakness or fatigue.

 2. Age ≤14 years.

 3. Severe anxiety, depression or schizophrenia.

 4. Cognitive impairment or mini-mental state examination (MMSE) score ≤24.

 5. Severe systemic illness with life-expectancy less than 4 years.

 6. Unwillingness to consent for collection of biological samples.

 7. Inability to provide informed consent.